Reversed metabolic reprogramming as a measure of cancer treatment efficacy in rat C6 glioma model
Authors:
Open Access
- 12 December 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (12) , e0225313
Abstract
Metabolism in tumor shifts from oxidative phosphorylation to inefficient glycolysis resulting in overproduction of lactate (Warburg effect), and cancers may be effectively treated if this imbalance were corrected. The aim of this longitudinal study of glioblastoma in a rat model was to determine whether the ratio of lactate (surrogate marker for glycolysis) to bicarbonate (for oxidative phosphorylation), as measured via in vivo magnetic resonance imaging of hyperpolarized 13C-labeled pyruvate accurately predicts survival. C6 Glioma implanted male Wistar rats (N = 26) were treated with an anti-vascular endothelial growth factor antibody B20.4.1.1 in a preliminary study to assess the efficacy of the drug. In a subsequent longitudinal survival study, magnetic resonance spectroscopic imaging (MRSI) was used to estimate [1-13C]Lactate and [1-13C]Bicarbonate in tumor and contralateral normal appearing brain of glioma implanted rats (N = 13) after injection of hyperpolarized [1-13C]Pyruvate at baseline and 48 hours post-treatment with B20.4.1.1. A survival of ~25% of B20.4.1.1 treated rats was noted in the preliminary study. In the longitudinal imaging experiment, changes in 13C Lactate, 13C Bicarbonate and tumor size measured at baseline and 48 hours post-treatment did not correlate with survival. 13C Lactate to 13C Bicarbonate ratio increased in all the 6 animals that succumbed to the tumor whereas the ratio decreased in 6 of the 7 animals that survived past the 70-day observation period. 13C Lactate to 13C Bicarbonate ratio (Lac/Bic) at 48 hours post-treatment is highly predictive of survival (p = 0.003). These results suggest a potential role for the 13C Lac/Bic ratio serving as a valuable measure of tumor metabolism and predicting therapeutic response.Keywords
Funding Information
- The Lucas Foundation
- General Electric Healthcare
- National Institutes of Health (R01 CA17683603)
- National Institutes of Health (R01 CA17683603)
- National Institutes of Health (R01 EB01901802)
- National Institutes of Health (P41 EB01589121)
- National Institutes of Health (S10 OD012283)
This publication has 31 references indexed in Scilit:
- Probing Early Tumor Response to Radiation Therapy Using Hyperpolarized [1-13C]pyruvate in MDA-MB-231 XenograftsPLOS ONE, 2013
- Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review)Oncology Letters, 2012
- Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastomaNeuroImage, 2012
- Tumor imaging using hyperpolarized 13C magnetic resonance spectroscopyMagnetic Resonance in Medicine, 2011
- Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1‐13C]pyruvate and 13C magnetic resonance spectroscopic imagingMagnetic Resonance in Medicine, 2010
- Fast dynamic 3D MR spectroscopic imaging with compressed sensing and multiband excitation pulses for hyperpolarized 13C studiesMagnetic Resonance in Medicine, 2010
- Cerebral Dynamics and Metabolism of Hyperpolarized [1-13C]pyruvate Using Time-Resolved MR Spectroscopic ImagingJournal of Cerebral Blood Flow & Metabolism, 2010
- Application of subsecond spiral chemical shift imaging to real‐time multislice metabolic imaging of the rat in vivo after injection of hyperpolarized 13C1‐pyruvateMagnetic Resonance in Medicine, 2009
- Understanding the Warburg Effect: The Metabolic Requirements of Cell ProliferationScience, 2009
- On the Origin of Cancer CellsScience, 1956